Core Insights - BioRestorative Therapies, Inc. has received a Notice of Allowance for a new patent application from the European Patent Office, which covers key aspects of its ThermoStem® metabolic disease platform, expected to provide protection until April 29, 2040 [1][3] Patent and Technology - The new patent covers a method for creating a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate [2] - The patent allowance validates the advancements made in the metabolic disease program, with a focus on transforming the treatment landscape for obesity and related metabolic diseases [3] Market Opportunities - The company sees a significant market opportunity for ThermoStem®-based BADSCs, particularly in regions dominated by GLP-1 treatments for obesity [3] - BioRestorative is in discussions with a commercial stage regenerative medicine company regarding a potential license of its ThermoStem® metabolic intellectual property [3] Clinical Development Programs - BioRestorative's core clinical development programs include: - Disc/Spine Program (brtxDISC™): Focused on treating painful lumbosacral disc disorders using BRTX-100, which is derived from a patient's own cultured mesenchymal stem cells [4] - Metabolic Program (ThermoStem®): Developing therapies targeting obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue [5] BioCosmeceuticals - The company operates a commercial BioCosmeceutical platform, offering a cell-based secretome product designed to reduce fine lines and wrinkles, with plans to expand its product offerings [6][7]
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program